Immix Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMX research report →
Range $19 – $25
Price Chart
About the company
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases.
- CEO
- Ilya Rachman
- IPO
- 2021
- Employees
- 21
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on IMMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $715.93M
- P/E
- -14.95
- Fwd P/E
- 188.00
- PEG
- 1.12
- P/S
- 0.00
- P/B
- 3.67
- EV/EBITDA
- -12.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.44%
- ROIC
- -18.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,956,415
- Net Income
- $-29,438,613-36.2%
- EPS
- $-0.89-17.1%
- OCF Growth
- -64.0%
- FCF Growth
- -56.4%
- 52W High
- $13.20
- 52W Low
- $1.94
- 50D MA
- $9.82
- 200D MA
- $7.89
- Beta
- 0.11
- RSI (14)
- 72
- Avg Volume
- 1.91M
No earnings-call transcripts are available for IMMX yet.
- Free Float
- 79.8%
- Shares Outstanding
- 54.40M
- Float Shares
- 43.40M
of shares held by institutions
69 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 4.80M | ▲ 880.43K |
| Vanguard Group Inc | 1.10M | ▲ 365.65K |
| Cibc Private Wealth Group, LLC | 40.00K | ▲ 30.00K |
| Cwm, LLC | 1.00K | 0 |
Held by 98 ETFs
Biggest fund positions in IMMX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 22, 26 | Adams Helen C. | other | 6,250 |
| May 22, 26 | Adams Helen C. | other | 12,500 |
| May 22, 26 | Ng Carey | other | 6,250 |
| May 22, 26 | Ng Carey | other | 12,500 |
| May 22, 26 | Marquet Magda | other | 6,250 |
| May 22, 26 | Marquet Magda | other | 12,500 |
| May 22, 26 | Morris Gabriel S | other | 500,000 |
| May 22, 26 | CHANG NANCY T | other | 6,250 |
| May 22, 26 | CHANG NANCY T | other | 12,500 |
| May 22, 26 | Rachman Ilya M | other | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMMX coverage
Recent articles, reports, and earnings notes.
No research on IMMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMX report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
prnewswire.com · Aug 13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
globenewswire.com · Aug 11
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
prnewswire.com · Aug 6
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
businesswire.com · Aug 6
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
globenewswire.com · Aug 4
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
globenewswire.com · Aug 4
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
prnewswire.com · Jul 30
IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses
newsfilecorp.com · Jul 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.